Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Helsinn Healthcare SA
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02383810CT.gov Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID) | — | Completed | — | — | — |
NCT01543451CT.gov Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diarrheal Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Elsiglutide (this asset) | Helsinn Healthcare SA | P2 | B · 62 |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | University of Southern California | P3 | BB |
| Irinotecan | Roswell Park Cancer Institute | P3 | BB |
| Loperamide | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P3 | BB |
| Crofelemer | Napo Pharmaceuticals, Inc. | P3 | BB |
| Sulfasalazine | Alliance for Clinical Trials in Oncology | P3 | BB |
| L-Ofloxacin | Children's Oncology Group | P3 | BB |
| Colesevelam | Memorial Sloan Kettering Cancer Center | P2 | B |
| Sandostatin | Novartis Pharmaceuticals | P4 | B |
+16 more in the Diarrheal Disease cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-University of Southern CaliforniaBB
- IrinotecanRoswell Park Cancer InstituteBB
- LoperamideSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityBB
- CrofelemerNapo Pharmaceuticals, Inc.BB
- SulfasalazineAlliance for Clinical Trials in OncologyBB
Citation
Floatz Terminal. Elsiglutide in Diarrheal Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/elsiglutide-diarrheal-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →